No Benefit for MRI-Guided Treat-to-Target Strategy in Rheumatoid Arthritis
Data do not support the use of an MRI-guided treat-to-target strategy for treating patients with rheumatoid arthritis.
Data do not support the use of an MRI-guided treat-to-target strategy for treating patients with rheumatoid arthritis.
The ACR is urging CMS to adopt safeguards to protect Medicare Advantage beneficiaries from step therapy.
Pelvic orientation was adjusted by global spinal alignment in patients with ankylosing spondylitis.
The American College of Rheumatology and Association of Physicians of Great Britain and Ireland have highlighted unmet needs and challenges of connective tissue disease-associated interstitial lung disease.
The FDA has granted Fast Track designation for GLPG1972/S201086 for the treatment of osteoarthritis.
Health and social service utilization decreased in immigrant communities after the 2016 presidential election.
The ACR and EULAR have developed draft classification criteria for giant cell arteritis and Takayasu arteritis.
Treatment with filgotinib over 24 weeks resulted in significant improvements in the signs and symptoms of RA among patients with inadequate response or intolerance to biologic DMARDs.
Experts at the 2018 ACR/ARHP Annual Meeting discuss whether hydroxychloroquine dosing should be more than 5 mg/kg in patients with systemic lupus erythematosus.
The genetic risk score may have lower costs than current testing methods.